Hematology

CHESHIRE, Conn. December 10, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myasthenia gravis (MG), a rare, debilitating neurologic disorder. In patients with MG, uncontrolled complement activation due to antibodies […]

New Analyses Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults with aHUS With or Without Identified Genetic Mutations Observational Data Highlight Importance of High Sensitivity Flow Cytometry to Enable Reliable Detection of PNH Cells CHESHIRE, Conn. December 8, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data that continue […]

HemOnc experts validate unmet need and performance of new ThunderBolts Myeloid NGS Panel at ASH 2014 BILLERICA, Mass. — December 5, 2014 — RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced the formation of the RainDance HemOnc Consortium, composed of a select group of hematologic clinical research […]

Secure, real-time access to ClonoSIGHT™ test results, order status, patient MRD trends SOUTH SAN FRANCISCO, Calif. DECEMBER 4, 2014 – Sequenta, Inc. today announced the launch of its new physician portal, the ClonoSIGHT Secure Portal (https://results.clonosight.com). The HIPAA-compliant online portal enables physicians to more effectively integrate the ClonoSIGHT process, an ultra-sensitive, next-generation sequencing-based technology for […]

Final Evaluation Determination Confirms that Soliris is a “Very Effective Treatment for aHUS with Significant Value to Patients” Final Evaluation Determination Includes the Same Conditions Discussed in Draft Recommendation, Including Establishment of an Expert Center and a Robust System to Monitor Patients Receiving Treatment CHESHIRE, Conn. November 27, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today […]

CHESHIRE, Conn. November 25, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder. In patients with NMO, chronic, uncontrolled complement activation results in severe […]

SOUTH SAN FRANCISCO, Calif. NOVEMBER 17, 2014 – Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical […]

– Multiple Clinical Presentations at Kidney Week 2014 – – Studies Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults Regardless of Dialysis or Transplant History – – New aHUS Registry Data Enhance the Understanding of aHUS – CHESHIRE, Conn. November 15, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data […]

15 presentations focus on next-generation sequencing-based MRD detection in a range of blood cancers, including diffuse large B-cell lymphoma and multiple myeloma SOUTH SAN FRANCISCO, Calif. NOVEMBER 6, 2014 – Sequenta, Inc. and its academic collaborators will present data on the ClonoSIGHT™ minimal residual disease (MRD) test in one oral and 14 poster presentations at […]

CHESHIRE, Conn. November 6, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present data from clinical studies of Soliris® (eculizumab) in patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening and ultra-rare diseases caused by chronic uncontrolled complement activation, as well as data from the Global aHUS […]